EVE Health Group outlines its platform strategy at Coffee Microcaps 2026
At the Coffee Microcaps Conference on 22 September 2026, EVE Health Group (ASX: EVE) presented its investment case as an ASX-listed Australian life sciences company building a commercial-stage pharmaceutical reformulation business. The presentation outlined how EVE is developing a proprietary nano-emulsion platform to improve established generic medicines, with lead product Libbo (vardenafil oral dissolving film) already available via SAS-B in Australia. At the time of the presentation, EVE carried a market capitalisation of A$5.6m and a share price of A$0.016 (as at 17 September 2026).
When big ASX news breaks, our subscribers know first
The problem with current ED treatments — and the gap EVE is targeting
The presentation detailed a global erectile dysfunction (ED) market of considerable scale. According to figures cited in the presentation, 322 million men were affected by ED globally in 2025, underpinning a USD 5.3 billion global ED drug market. Despite this scale, the market is characterised by high patient attrition, with more than 50% of patients stopping purchases of PDE5 inhibitors (phosphodiesterase type 5 inhibitors, the drug class used to treat ED).
Management attributed this discontinuation problem to three friction points common across existing treatments: slow onset of 1 hour or more, food effects of up to 35% for selected tablet formats, and the planning burden associated with timed dosing. The presentation summarised the competitive landscape across current treatments:
| Drug | Brand / Format | Generic? | Typical Onset | Patient Friction |
|---|---|---|---|---|
| Sildenafil | Viagra | Yes | 1 hr+ | Food effect / planning burden |
| Tadalafil | Cialis | Yes | 1 hr+ | Long duration, slower onset |
| Vardenafil | Levitra | Yes | 45–60 min | Timing variability remains |
The presentation noted that EVE is not fighting for share — it is picking up patients the incumbents are already losing.
Libbo and the nano-emulsion platform — how EVE’s technology works
The presentation introduced Libbo, EVE’s vardenafil oral dissolving film (ODF), as the company’s lead commercial product. Libbo is currently supplied under TGA SAS-B via LibX.com.au, with hubMed providing telehealth prescribing and Chemist2U handling pharmacy fulfilment.
Libbo’s Australian launch in early 2026 activated an integrated digital-to-delivery model spanning telehealth prescribing via hubMed and direct pharmacy fulfilment through Chemist2U, establishing the commercial infrastructure now generating SAS-B revenue.
Management explained that the underlying technology involves a proprietary process that converts poorly soluble molecules into a stable nano-emulsion, which is then delivered via oral film or spray for transmucosal absorption. This approach is designed to improve effective solubility and support faster, more consistent systemic exposure compared to conventional tablet formats.
The presentation cited an onset time of approximately 15 minutes for Libbo, compared to 45–60 minutes for standard tablets. The source caveat, as stated in the presentation, must be noted: “Onset is based on formulation design and an early 10-person observational study. Clinical validation is progressing via bioequivalence study.”
Management emphasised that Libbo functions as proof of concept for a broader platform. The same nano-emulsion system is designed to apply across a wide range of poorly soluble drugs. The platform’s confirmed attributes, as presented, include:
- Enhanced Solubility
- Improved Bioavailability
- Fast-Onset Formats
- Patent-Pending
- Versatile
- Reduced Patient Variability
Pipeline, milestones and the investment case
The presentation outlined a structured near-term milestone schedule across EVE’s portfolio:
| Timing | Milestone | Detail |
|---|---|---|
| Q1 2027 | BE Study Commences | Libbo bioequivalence study initiated — confirming step toward full product registration. |
| H1 2027 | PE Program Update | Pre-BE progress update on standalone premature ejaculation program. |
| H2 2027 | Apixaban Pre-BE | Completion of pre-BE work on Apixaban reformulation program. |
| H2 2027 | Registration Submission | Libbo product registration submission expected following BE study completion. |
The presentation noted that timing reflects the current corporate planning view and is subject to clinical, regulatory and operational dependencies.
The Libbo pilot pharmacokinetic study was formally initiated in June 2026, with subject recruitment underway and results expected in Q3 CY2026, representing the first clinical step in the bioequivalence development programme ahead of the pivotal trial required for full TGA registration.
Beyond Libbo, EVE’s pipeline spans two franchises. The Men’s Health Franchise includes Libbo (Vardenafil ODF), a PE Program, an ED/PE Combination, and a BPH Program. The Cardio-Metabolic and Future Programs include reformulations of Apixaban, Rosuvastatin, and Atorvastatin.
The presentation also highlighted the patent cliff as a source of future pipeline candidates. Key targets identified include:
| Target Medicine | Global Sales | Patent Expiry | EVE Relevance |
|---|---|---|---|
| Apixaban (Eliquis) | USD 12.2B | 2026 | Pre-BE development |
| Rivaroxaban (Xarelto) | USD 6.8B | 2025 | Screening |
| Xtandi (Enzalutamide) | USD 6.3B | 2027 | Screening |
| Farxiga (Dapagliflozin) | USD 6.0B | 2025 | Screening |
| Imbruvica (Ibrutinib) | USD 4.9B | 2027 | Screening |
Market values are directional, based on referenced 2023/2024 global sales sources.
The presentation framed EVE’s intended revenue progression across three stages: SAS-B Revenue (current) moving to Licensing Milestones (near-term), and ultimately to Scaled Partner-Led Revenue (post-registration). Global partner conversations were noted as underway across Asia, the Middle East, Europe and North America, though the presentation described these as conversations rather than signed agreements.
The company’s corporate snapshot at the time of the presentation was as follows:
- ASX: EVE | Share price: A$0.016 (17 September 2026) | Shares on issue: 352 million
- Market capitalisation: A$5.6 million | Cash: A$1.2 million (30 June 2026) | Debt: Nil
- Enterprise value: A$4.4 million
Ready to Explore EVE Health Group’s Nano-Emulsion Platform and Pipeline Potential?
EVE Health Group is advancing a proprietary nano-emulsion reformulation platform, with lead product Libbo already generating SAS-B revenue in Australia and a structured milestone schedule targeting bioequivalence studies, product registration, and expanded pipeline programmes through 2027.
Investors seeking to understand how EVE’s technology could unlock licensing and scaled revenue opportunities across men’s health and cardio-metabolic markets can explore the full investment case at the EVE Health Group website.